Questions worth asking.

Read the unit beside the number. A can total, a per-pouch amount and a per-serving amount describe different quantities. For example, 20 pouches containing 40 mg each would total 800 mg in the can; this arithmetic example is not a proposed serving. A brand brief should specify all three fields and check that the artwork, finished-product assay and pouch count agree. Avoid a front-panel number that needs a social-media explanation.

• FDA: Spilling the Beans — How Much Caffeine is Too Much?

Multiply the concentration in mg/g by the specified mass basis in grams per pouch. At 10 mg/g and 0.5 g of the material to which that concentration applies, the calculated content is 5 mg. Check whether the quoted mass includes the wrapper, and whether the assay is reported on a wet or dry basis. This gives a content calculation, not the amount absorbed or a prediction of the experience.

A row of dots is a brand scale unless the company defines a common measurement behind it. Compare the named active, its amount per pouch, units per serving and the measurement basis first. Two products with identical dots may have different compositions. When commissioning private-label artwork, place the numerical content and substance name where buyers can find them without interpreting a decorative strength scale.

Yes. The exposure review must include caffeine from drinks, supplements and every pouch ingredient, including botanical sources. FDA notes that sensitivity varies with factors such as medicines and medical conditions. A product-development team should prepare a total-intake scenario for label review; this page does not set a personal daily allowance. Consumers who are uncertain about combined use should discuss their full intake with a healthcare professional.

• FDA: Spilling the Beans — How Much Caffeine is Too Much?

A reported lack of effect cannot identify an underfilled pouch. Check fill weight separately from active content, then investigate the retained lot, storage history and the product’s release characteristics. A sensory review should record the conditions without encouraging the person to add more pouches to chase an effect. For a brand, this complaint needs both an analytical route and a customer-care response; taste or perceived stimulation alone cannot verify the label.

Yes, that is a suitable formulation brief to discuss. Specify caffeine as the only intended functional active, then list the exclusions explicitly. The formula will still need a carrier and a suitable sensory system, so “caffeine only” should not imply a pouch filled with pure caffeine. Decide whether coffee, tea or guarana materials are wanted, and check every ingredient against the exclusion list before sampling.

That promise would need evidence that matches the product and the claim. A convenient format does not establish safe performance during a shift or remove the effects of inadequate sleep. For a night-shift product brief, review intended users, the proposed use pattern, other caffeine sources and the warnings with the destination-market adviser. Avoid claims that a pouch makes a tired person safe to drive or operate machinery.

• FTC: Health Products Compliance Guidance
• FDA: Spilling the Beans — How Much Caffeine is Too Much?

Use a distinct product name and prominent substance declaration, supported by more than a change of lid color. Test the label at shelf distance, on a small phone screen and in a mixed order. Give each version a separate SKU and barcode, and verify the packing line against the approved artwork. A nicotine-free statement belongs to a specific verified formula; a familiar flavor name should never substitute for checking the active.

That can be set as a sensory target. Start with the filled base and compare sweetness onset, lingering sweetness and mint aroma separately. A change of sweetener alone may leave bitterness from the active or carrier exposed. Use blind comparisons at agreed intervals, and record which aftertaste the panel is rejecting. The approved target should describe the experience in ordinary terms rather than rely on “clean taste” as an unmeasured promise.

Yes, low-cooling and non-mint directions can be explored. Distinguish the mint aroma from the cooling ingredient: removing one may leave the other. Evaluate the uncooled base before selecting a fruit, coffee or neutral direction, because cooling may previously have covered bitterness. Approve the sensory change on the final pouch with its intended moisture and active system. An absence of mint does not establish that a formula will suit every user.

A dominant coffee base, bitterness or lingering sweetener can obscure the differences between top notes. Compare the base without added flavor against each proposed variant under the same conditions. Assess whether the distinction survives later in the evaluation, rather than judging only the aroma of a freshly opened can. If two variants cannot be reliably distinguished, revise the sensory brief before commissioning separate artwork and inventory.

A reference can help define aroma, cooling onset, sweetness and duration. Describe those attributes in a brief and develop an original target without copying another brand’s identity or claiming to supply its formula. Use authorized reference samples for comparisons, record their market and version, and approve your own final formulation. A flavor name alone leaves too much room for disagreement between the brand, flavor house and manufacturer.

Record the lot, use conditions, pouch integrity and when the complaint begins. Then compare moisture distribution, fill particle size, soluble ingredients and web permeability against the approved sample. A bench wetting or release comparison may help identify a formulation change, but it does not establish clinical tolerability. Advise a person experiencing discomfort to stop using the product; persistent or significant symptoms need professional assessment.

The fill can redistribute as it wets, while the web and seams determine how well the pouch retains its shape. Compare the approved reference with the complaint sample for wet strength, fill distribution and seam condition. Avoid assuming that collapse means the active has dissolved correctly. For development, include a defined wet-handling evaluation and describe acceptable shape retention, rather than approving comfort from a dry pouch alone.

Treat taste preference and the reported symptom as separate parts of the complaint. Ask the customer to stop using the affected product, retain the pack and provide the lot and timing through the appropriate support channel. The quality review should examine the actual composition and related complaints without diagnosing the cause from an email. A less-sweet reformulation may address preference, but it cannot by itself establish that the symptom has been resolved.

Use a staged sensory brief: compare a small set of distinct directions, narrow the field, then evaluate the chosen direction in the intended finished format. Define panel suitability and record preference separately from defects such as leakage or a bitter spike. For regulated or active products, the sampling arrangement also needs an appropriate safety and market review. Sunova’s 91 commonly produced directions are a starting library; custom development can explore the broader 5,100+ flavor capability.

Adding label amounts gives a nominal total, but it leaves release, route, timing and co-ingredient exposure unresolved. Review each study’s ingredient identity and administration conditions before proposing a comparison. A larger pouch count also multiplies every other ingredient in the formula. For a development project, prepare a serving-level mass balance and an evidence assessment before sensory sampling; do not use repeated consumption as a substitute for finished-product evidence.

• FTC: Health Products Compliance Guidance

Ingredient count is a poor selection rule. A longer blend leaves less room for each component and can complicate taste, compatibility testing and claim review. Start with the intended purpose and the evidence requirements, then decide which ingredients have a defensible role at the proposed content. A simpler formula can be easier to investigate and control. The finished product still needs its own quality specification and an appropriate assessment of any claimed benefit.

• FTC: Health Products Compliance Guidance

No route claim can be established from placement alone. Identify the extract and the compounds being discussed, then distinguish release into saliva from permeation through tissue and from a measured human response. Capsule or animal findings cannot fill every gap in that chain. Ask what evidence exists for the actual formulation before using “buccal delivery” or a speed claim in marketing. A pouch can be developed without asserting an unverified absorption advantage.

• FTC: Health Products Compliance Guidance

“Herbal” does not establish universal suitability. NCCIH identifies safety limitations and possible interactions for ashwagandha. A brand should specify the extract, intended population and proposed use pattern, and have the relevant warnings reviewed for the destination market. Neither a familiar botanical name nor a pleasant sample removes that work. A customer taking medication or managing a health condition should discuss the specific product with a qualified healthcare professional.

• NCCIH: Ashwagandha — Usefulness and Safety

Do not present a commercial nootropic pouch as a substitute for prescribed treatment. A discussion of choline ingredients or subjective focus does not validate use for a diagnosed condition. Product enquiries should stay within the agreed development scope, while an individual considering a treatment change should speak with their treating clinician. For brand copy, remove implied medicine-replacement claims as well as explicit disease names when the product lacks the required authorization and evidence.

• FDA: Questions and Answers on Dietary Supplements
• FTC: Health Products Compliance Guidance

Compare the exact B12 form, content per serving, route of use, stability and the practicality of the finished unit. A small, convenient format can be a valid design objective, but it does not establish superior absorption. NIH ODS notes that oral and sublingual B12 have not shown different efficacy in the evidence it summarizes. That observation does not validate a particular pouch or film. Keep any finished-product performance claim tied to appropriate evidence.

• NIH ODS: Vitamin B12, Health Professional Fact Sheet

Specify the intended claim first. A strain studied for one outcome or route cannot automatically substantiate another. A useful brief names the strain, the intended endpoint and the viable count required through the proposed shelf life. The stability work must include the finished pouch and package. If an oral-health claim is proposed, review evidence for that use rather than borrowing a digestive-health narrative from a capsule containing a similarly named organism.

• NIH ODS: Probiotics, Health Professional Fact Sheet

The active shares a limited space with the carrier, sensory ingredients and, in a film, the film-forming system. A high-mass serving can create a bulky pouch or a film with poor handling and disintegration. Build a complete mass balance before promising an equivalent unit. The feasible amount depends on the ingredient and formulation; there is no single loading limit for every product. A different format may be the better brief.

They are separate parts of the specification. The fill may contain a cellulose carrier, while the wrapper is a nonwoven web with its own fiber, binder and sealing requirements. Request a composition declaration for each part and identify any additional processing materials. A supplier’s statement about the carrier cannot establish the composition of the complete wrapper. Keep both records linked to the approved product version.

• FDA: Food Ingredient and Packaging Inventories

A cotton preference can be investigated, but the material still needs to meet the product’s contact, release and sealing requirements. Ask for the actual fiber composition and any binder or coating, then evaluate wet strength and compatibility with the filled formula. “Natural” is not a performance specification. Approve a representative filled sample and the supporting material records before treating a proposed cotton web as interchangeable with the current wrapper.

No. Photograph and retain the affected units, identify the lot and compare them with a reference sample. The investigation should distinguish surface fibers, a damaged seam and an unrelated foreign material, using suitable inspection methods. Establish an acceptance criterion for the actual web and finished pouch. A comment that the product is “just paper” cannot close a material or foreign-body complaint.

These formats have different design purposes. An oral strip is formulated to disintegrate in the mouth. A conventional pouch is intended to retain its fill during the specified use and be removed afterward, according to its label. If the wrapper flakes, breaks down or releases fill unexpectedly, retain the pack for a quality investigation. A nicotine-free formulation does not turn a conventional pouch wrapper into an edible film.

It may be possible, depending on the formulation, but shrinking the pouch changes the available space and the concentration of its contents. Assess powder handling, dose uniformity, seam clearance and the sensory profile together. A drawing that looks discreet does not establish a workable product. Compare production-representative samples at the intended active content, and keep appearance separate from claims about strength or tolerability.

Treat the seam as a design variable. Record which edge is uncomfortable, then compare seal width, edge condition, web stiffness and filled thickness with the approved sample. Pressed and ultrasonic constructions can both be evaluated against the same criteria. A useful approval includes inspection after wet handling, because a dry seam may feel different once the web is hydrated. Changing the seam requires a fresh integrity check as well as a sensory comparison.

Define exactly what is being claimed and which parts of the product it covers. Material composition records answer a different question from testing for particles under specified conditions. Ask the laboratory what its method can identify, the relevant size range, blanks and reporting limits before commissioning a test. Avoid converting “cellulose-based” into an unqualified absence claim. Any public environmental or material claim needs evidence that matches its wording.

• FTC: Environmental Claims — Summary of the Green Guides

A brand may sell different formats by market or product version. Do not use the brand name as a dimensional standard. For an OEM reference, identify the version and measure the actual pouch length, width, thickness and seam allowance, then approve your own drawing and samples. Sunova can discuss several pouch constructions and can formats; the chosen combination must be evaluated with the intended fill and count.

Place the affected stock on hold while the excursion is assessed. Record the likely temperatures, duration, lot and package condition, then compare them with the approved storage specification and available stability data. Select any examination or testing through the quality team. Normal appearance or a remaining mint smell is insufficient to release the batch. An affected consumer pack should be referred to the brand rather than judged safe from a forum reply.

Repeated temperature changes can expose a package to condensation when it is opened, so refrigeration should follow the specific product’s storage instructions. Evaluate the intended storage pattern with the actual closure and formulation. A brand planning chilled distribution should assess both storage and the transition to use. Do not extend a shelf-life claim merely because samples were kept cold, or apply one tobacco-snus storage recommendation to every nicotine-free pouch.

Agree a minimum remaining period in the purchase specification and define the point at which it is measured, such as arrival at the named warehouse. Allow for transit, customs, distributor holding time and the expected sales cycle. Verify manufacturing and expiry coding against the batch records before shipment. There is no universal remaining-life number for every route or customer, and an ingredient’s expiry date cannot substitute for the finished product’s supported shelf life.

Keep the pack and record its lot, seller and storage history. A change may involve flavor, packaging, handling or a product-quality defect; smell alone cannot identify which. The brand should compare retained samples and inspect the closure and relevant batch records before selecting tests. If the product seems abnormal, stop using it while the concern is assessed. A reseller’s reassurance should not replace a traceable investigation.

No. Uncontrolled rehydration changes the finished product after release and may alter distribution of soluble ingredients, microbial conditions and package performance. Record the affected lot and storage history, then ask the manufacturer to assess disposition under its quality procedures. If moisture adjustment is part of a manufacturing process, it belongs in the controlled process with defined limits and testing. A home-restoration tip is not an acceptable retail rework instruction.

• FDA: Water Activity (aw) in Foods

Keep used and unused products separate. A dedicated catch compartment, where provided, is for temporary containment before appropriate disposal; it is not a way to return used material to fresh stock. Package development should check that the compartments remain distinct during ordinary handling. Disposal instructions should be clear, and the container and its used contents must stay out of the reach of children.

Drying does not restore a used pouch to its original hygienic state or establish how much active remains. The wrapper and seam may also have changed during use. Follow the product’s disposal instructions and do not present reuse as a controlled way to reduce a serving. For brands, customer instructions and the catch-lid design should make single-use handling clear instead of leaving users to infer it from a compartment.

It can be assessed as a packaging project, with a separate specification for the refill barrier and the reusable container. Define cleaning instructions, intended reuse cycles, closure performance and how lot and expiry information stay with the product after transfer. Check the consequences of mixing old and new stock. A reusable outer can does not remove the need to protect the refill or demonstrate the finished product’s stability.

Specify them separately. A strip’s film-forming ingredient is part of the consumed formulation; the sachet is a protective packaging structure. Names such as HPMC or pullulan describe potential film ingredients, not the full composition or suitability of the product. Request the approved formula, ingredient grades and separate packaging declaration. Avoid using “plastic-free” across the complete pack unless the evidence covers every component and the exact claim.

• FDA: Food Ingredient and Packaging Inventories

A moisture-sensitive film can change when exposed to ambient humidity. Record the exposure conditions and compare the sample with an unopened retained unit. Evaluate tack, handling and disintegration rather than assuming that a sticky strip still meets specification. The package and instructions should support the intended use after opening. For manufacturing, establish an acceptable time between opening the protective pack and the next operation under defined environmental conditions.

A plasticizer can change flexibility, but increasing it may also change tack, moisture response and disintegration. Compare candidate formulations against several acceptance criteria and assess them in the intended barrier pack. The ratio used in a published laboratory film is a starting point for research, not a universal production recipe. Confirm handling after storage and through the converting and packing process, rather than approving only a freshly cast sheet.

That format requires its own protection and handling assessment. Repeated opening exposes the remaining units to the environment, and stacked films may adhere or be difficult to separate. Compare the proposed container with a unit pack for moisture protection, unit retrieval and stability under an appropriate in-use simulation. Do not transfer shelf-life evidence from individual sachets to a bottle without evaluating the change.

Those are different outcomes, and a review of one does not establish the other. A melatonin film’s ability to disintegrate is a quality attribute; it does not demonstrate an all-night sleep benefit. A brand should define the proposed claim and assess the evidence that fits it. Persistent sleep difficulties belong in a clinical conversation, and a product description should not promise to resolve chronic insomnia from the format alone.

• NCCIH: Melatonin — What You Need To Know

Record the report through the product’s safety and complaint process, including the lot and the customer’s description of use, and review it with the appropriate qualified personnel. NCCIH lists daytime drowsiness among reported short-term side effects of melatonin; an online comment cannot establish the cause of an individual event. Do not answer by suggesting that the customer raise the amount. The formulation, instructions and warnings should be reviewed against the product’s intended market.

• NCCIH: Melatonin — What You Need To Know

It can be a useful convenience target when the product is designed and labeled for that use. Confirm that a representative user can remove one intact unit and that the film meets its disintegration and handling specification. Convenience should be assessed separately from claims about faster absorption or better results. It also does not establish suitability for someone with a swallowing disorder, who may need individualized professional advice.

A spray and a film are different formulations. Match the active, route, dose, contact conditions and study population before proposing any bridge between them. A film disintegration test measures a physical event, while human pharmacokinetic work measures exposure over time. Keep those endpoints distinct in a technical brief. Published work on another format can help frame research questions, but it does not establish a Sunova film’s onset or bioavailability.

• FTC: Health Products Compliance Guidance

Identify the approved formula version, raw-material grades, sensory target, pouch construction, pack configuration and test methods in writing. Also record any pilot operations that differ from the planned line and the work needed to assess those differences. Keep a signed reference sample under suitable storage. Approval of a handmade sample should be linked to a defined production plan, so both parties understand which characteristics have been demonstrated and which remain to be confirmed.

It may remove a custom-print or tooling constraint, provided the stock can is suitable for the selected product. Compare the closure, capacity, labeling space and barrier needs before treating it as a shortcut. Keep the pilot identifiable with its version and lot information. A later move to a decorated or different can needs a controlled review, including any effect on stability or filling operations.

A common base can be evaluated, but each finished flavor still needs its own formula record and approval. Flavor additions may change flow, moisture, assay recovery or sensory balance, so a shared base does not establish identical processing behavior. Define when the blend is divided, how each variant is traced and which testing applies. Confirm the project’s minimums for formula, flavor and packaging separately before building the launch plan.

Yes, buyer-nominated materials can be discussed. Supply the exact grade, manufacturer, specification, allergen information, available testing and supply conditions for review. The manufacturer must assess suitability for the intended pouch or film process; a sample and a COA alone do not complete that assessment. Agree who purchases the material, manages changes and handles a supply interruption before fixing the commercial formula.

The service boundaries vary by company. Map the project from material approval through blending, pouch forming, can filling, labeling, testing and release, and name the responsible party at each handover. If more than one business is involved, define custody, traceability and acceptance of the intermediate product. Ask for a written scope instead of assuming that “contract manufacturing” includes every operation needed to ship a finished retail pack.

A workable transfer may require more than an ingredient list: include quantities, grades, approved suppliers, process instructions, critical parameters, test methods, packaging specifications and change history. Access and transfer rights depend on the signed agreement and any licensed know-how. Define deliverables while negotiating development, and identify what can actually be shared. Receiving the files still leaves the new site’s process qualification and product approval work to be completed.

Put the substitution through change control before production. Compare identity, standardization, carriers, contaminants, sensory properties and the evidence behind the proposed claims. The alternative may require reformulation, new analytical work or a revised schedule. Keep the original formula version traceable and obtain the agreed approvals. An apparently similar ingredient name should not be used to make a silent replacement in a customer-approved product.

The quality agreement should define sampling, release criteria, investigation responsibilities and how rejected or disputed material is held. The commercial agreement should address the agreed remedies and the evidence required to apply them. Include sensory references and packaging requirements where they matter, rather than leaving acceptance to a broad phrase such as “good quality.” Set these terms before the production commitment, while the product and test scope are still being defined.

• FDA: Dietary Supplement CGMP Small Entity Compliance Guide

Match the product description, sample or lot identifier, dates and reported methods to the delivered pack and release records. Check the laboratory’s identity through an independent contact route if verification is needed. Ask how the sample was selected and submitted; a genuine report on a different sample cannot release your stock. Keep the original document and the link between sample, batch and shipment in the quality file.

A live walkthrough can help a buyer understand the named site, equipment and operating flow. Prepare questions about the specific pouch or film project and record which operations are in-house or subcontracted. A video visit cannot replace a product specification, quality agreement or suitable audit. Treat observations as one part of qualification and resolve unanswered questions with records or further assessment, without turning a marketing tour into a certification claim.

The finished batch introduces questions about mixing, portioning, processing and packaging that individual ingredient reports cannot answer. Select tests that address the product’s risks and label commitments, such as active content, unit consistency and relevant contaminants. The panel and sampling plan should be justified for the actual formula. Keeping raw-material records is essential, but it does not demonstrate that the assembled pouch or film meets its release specification.

• FDA: Dietary Supplement CGMP Small Entity Compliance Guide

Marketplace acceptance is a separate review and its requirements can change. Confirm the current rules for the exact product category and destination marketplace, then allocate responsibility for submitting and maintaining the requested records. A facility credential does not establish product legality, label compliance or platform eligibility. Avoid committing stock on the assumption that a general certificate settles every question; resolve the sales-channel requirements during project scoping.

Facility registration and finished-product evaluation are different matters. FDA explains that it does not issue or recognize private food-facility registration certificates as evidence of approval. Ask which product tests have actually been performed, by whom, and on which lot. Product-market requirements must be assessed separately. This distinction applies to website wording as well as a supplier’s sales document; registration should not be presented as FDA endorsement of a formula.

• FDA: Food Facility Registration and Private Registration Certificates

Do not assume that it does. Check the exact authorized product and applicable order against the proposed private-label arrangement, composition, packaging and marketing. FDA maintains a current list of authorized nicotine pouch products; a manufacturing relationship is not a substitute for that review. Sunova’s ability to discuss OEM production does not establish US authorization for a proposed SKU. Resolve the route to market before committing to a launch.

• FDA: Nicotine Pouch Products Authorized by the FDA

Personal reports do not establish a causal benefit for a different finished product. Any testimonial used in advertising also raises questions about permission, accuracy and what the overall message implies. Develop a claim review around the evidence for the product and proposed use, including implied promises in imagery or quotations. Community discussions are useful for discovering unanswered questions; they should not be converted into clinical substantiation or invented customer endorsements.

• FTC: Health Products Compliance Guidance

A target market may require different ingredient permissions, category treatment, language, warnings and responsible-business information. Review the exact formulation and intended use before adapting the artwork. Maintain approved market versions so a later formula or claim change reaches every affected label and web page. Export experience and multilingual website text can support communication, but they do not replace product-specific review for the place where the product will be sold.

• FDA: Questions and Answers on Dietary Supplements

Yes. The listed pouch families and oral film projects can be discussed under OEM, ODM or CDMO. The final formula, testing plan, packaging and commercial scope are agreed for the actual project; caffeine oral film remains an R&D project category.

They refer to different substances. A nicotine-free brief can still include caffeine from anhydrous caffeine, coffee, tea, guarana or yerba mate. A caffeine-free project needs a separate ingredient and testing specification.

No. The two claims should be specified and assessed independently. This site focuses on functional development directions; the approved formula and analytical requirements establish the final composition.

That can be discussed using a flavor-only, oral-care or selected botanical direction. Review every raw material, including botanical caffeine contributions, and agree how any absence claim will be substantiated.

No. Nicotine-free does not establish local tolerability. The complete formula, pH, flavor and cooling system, web, seal and intended contact conditions need evaluation. We do not make an irritation-free claim.

It depends on the formula, moisture, pouch material, flavor system, storage and evaluation conditions. Define a timed sensory test and compare samples; a fixed duration is not promised from the flavor name.

Actives, minerals, botanical extracts, sweeteners and flavor carriers can each contribute. Compare against an unflavored reference and score bitterness, astringency, sweetness and cooling separately.

Treat it as a product-quality failure to investigate. Review web compatibility, seal contamination, sealing parameters and package handling. Set integrity acceptance criteria for the actual finished pouch.

It can if botanical caffeine is omitted from the calculation. Use the actual ingredient assay, count all sources and verify the finished matrix with a suitable method.

No fixed equivalence is assumed. Composition, serving amount and the exposure from the intended route of use need their own assessment. Beverage comparisons do not validate a pouch dose.

No cessation or treatment claim is made here. Such claims require the appropriate product classification, evidence and authorization for the destination market.

No. They are commercial format descriptions that vary by brand, market and release. Approve the actual dimensions, fill weight, thickness and seal allowance on a drawing and physical sample.

No. Request the applicable test report, standard, sample configuration and current scope. A design name or symbol alone is insufficient.

Setup, material purchase, printing, tooling, line changeover and testing may be spread over fewer units. Ask for the actual project quotation and compare the same package and test scope.

No. The can workbook describes component packing quantities. Finished-product MOQ is confirmed separately for the formula, flavor, artwork and production scope.

Yes, custom directions can be discussed. Treat aroma, sweetness, cooling and aftertaste as separate variables and approve the final filled pouch.

No. They identify a sensory direction. The approved formula, supplier specifications and ingredient declaration establish composition and allergens.

No. Certificate scope, raw-material quality, finished testing and destination-market classification answer different questions. Review each for the actual product.

Shelf life is established for the final formula, package and storage conditions using an agreed stability program. A generic period from a reference formulation is not a finished-product guarantee.

Send the product family, target market, ingredient preferences, sensory direction, pouch format, can model and requested documentation. Price, MOQ and timing can then be scoped for that project.

No. Moisture, water activity, sensory requirements and packaging need to be defined for the selected format. The reference lists both WET and DRY nicotine and caffeine pouches.

It is the reference strength range in the product summary. Confirm whether each mg value is expressed per pouch, per finished unit or on another basis in the approved specification. It is not a consumer dosing instruction.

Specify nicotine-free, tobacco-free and caffeine-free requirements separately, with the intended market and ingredients. Agree the formula controls, analytical method and reporting limits used to support any absence claim.

Those are the listed reference options for melatonin oral strips. The reference pack is 20 strips per box, with 5,000 boxes per SKU. Final strength basis, composition, claims and market suitability require approval.

The supplied reference identifies caffeine strips as an R&D product, with a 25–50 mg reference range and custom-strength development. Commercial status, packing and quantities require confirmation.

These phrases describe search and development categories. They do not establish finished-product sleep, energy or cognitive benefits. Any label claim needs evidence for the actual composition and intended market.